

# HIV SEMI-ANNUAL SURVEILLANCE REPORT

## San Francisco Department of Public Health

### HIV Cases Diagnosed Through December 2021 and Reported Through February 2022

<b>Contents</b>	<b>Page</b>
Surveillance Summary.....	1
Figure 1. Diagnoses of HIV infection, HIV deaths and persons living with HIV by year .....	2
Figure 2. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS by year .....	2
Figure 3. Continuum of HIV care among persons newly diagnosed with HIV .....	3
Table 1. Diagnoses of HIV infection by age and year of initial HIV diagnosis.....	4
Table 2. Diagnoses of HIV infection stage 3 (AIDS) by age and year of AIDS diagnosis.....	5
Table 3. Diagnoses of HIV infection by gender and year of initial HIV diagnosis .....	6
Table 4. Diagnoses of HIV infection stage 3 (AIDS) by gender and year of AIDS diagnosis...	7
Table 5. Diagnoses of HIV infection by race/ethnicity and year of initial HIV diagnosis.....	8
Table 6. Diagnoses of HIV infection stage 3 (AIDS) by race/ethnicity and year of AIDS diagnosis.....	9
Table 7. Diagnoses of HIV infection by transmission category and year of initial HIV diagnosis.....	10
Table 8. Diagnoses of HIV infection stage 3 (AIDS) by transmission category and year of AIDS diagnosis.....	11
Table 9. Diagnoses of HIV infection, HIV deaths and persons living with HIV by year .....	12
Table 10. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS by year .....	13
Table 11. Persons living with HIV infection by age, gender and race/ethnicity.....	14
Table 12. Persons living with HIV infection by transmission category, gender and race/ethnicity.....	15

The HIV Surveillance Report is published semi-annually by the  
San Francisco Department of Public Health, Population Health Division  
Applied Research, Community Health Epidemiology, and Surveillance Branch (ARCHES)  
25 Van Ness Avenue, Suite 500, San Francisco, CA 94102; Phone (628) 217-6336, FAX (415) 431-0353

Director of Health: Grant Colfax, MD  
Director of Population Health Division: Susan Phillip, MD, MPH  
Director of ARCHES: Wayne Enanoria, PhD, MPH  
Director of HIV Surveillance Section: Ling Hsu, MPH

***The HIV Surveillance Report is accessible via internet:  
<http://www.sfdph.org/dph/files/reports/default.asp>***

# HIV SURVEILLANCE SUMMARY

## San Francisco<sup>a</sup> (as of 12/31/2021)

Persons living with HIV infection (all disease stages)	15,627
Persons living with HIV infection ever classified as stage 3 (AIDS)	8,763
Diagnoses of HIV infection, 2021	160
Deaths of persons diagnosed with HIV infection, 2021	270
Deaths of persons diagnosed with HIV infection ever classified as stage 3 (AIDS), 2021	198

## California<sup>b</sup> (as of 12/31/2019)

Persons living with HIV infection (all disease stages)	137,785
Persons living with HIV infection ever classified as stage 3 (AIDS) <sup>c</sup>	66,094
Diagnoses of HIV infection, 2019	4,396
Deaths of persons diagnosed with HIV infection, 2019	1,912
Deaths of persons diagnosed with HIV infection ever classified as stage 3 (AIDS), 2019 <sup>d</sup>	1,371

## United States<sup>e</sup> (as of 12/31/2019)

Persons living with HIV infection (all disease stages)	1,061,482
Persons living with HIV infection ever classified as stage 3 (AIDS)	NA
Diagnoses of HIV infection, 2019	36,801
Deaths of persons diagnosed with HIV infection, 2019	15,817
Deaths of persons diagnosed with HIV infection ever classified as stage 3 (AIDS), 2019 <sup>d</sup>	12,142

<sup>a</sup> Residents of San Francisco at time of HIV or AIDS diagnosis.


<sup>b</sup> California HIV Surveillance Report 2019. [https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OA\\_case\\_surveillance\\_reports.aspx](https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OA_case_surveillance_reports.aspx). Released 2/23/2021.

<sup>c</sup> Supplemental Tables to the California HIV Surveillance Report — 2019. [https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OA\\_case\\_surveillance\\_reports.aspx](https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OA_case_surveillance_reports.aspx). Released 3/16/2021.

<sup>d</sup> CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019. HIV Surveillance Supplemental Report 2021;26(No. 2). (Table 7f) <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published May 2021.


<sup>e</sup> CDC. HIV Surveillance Report, 2019; vol. 32. (Table 1b, 11b, 15b). <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published May 2021.

**Figure 1. Diagnoses of HIV infection, HIV deaths and persons living with HIV by year, San Francisco, 2002-2021\***




\* Reporting for recent years is incomplete. See Table 9 for actual numbers per year.

**Figure 2. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS by year, San Francisco, 1980-2021†**



† Reporting for recent years is incomplete. See Table 10 for actual numbers per year.

**Figure 3. Continuum of HIV care among persons newly diagnosed with HIV, San Francisco**



■ New diagnoses    
 ■ Linked to care within 1 month    
 ■ Viral suppression within 6 months

#### Month/Year of HIV Diagnosis

The month and year of HIV diagnosis are determined based on the earliest date of a positive HIV antibody/antigen test, detectable viral load, or physician-documented diagnosis in absence of sufficient laboratory evidence, and do not consider patient self-report of a positive HIV test. For other parts of this report that assess trends in HIV diagnoses, the year of initial HIV diagnosis takes into account self-report of HIV infection. Therefore, the numbers shown in Figure 3 may differ from other data presented in this report.

#### Linkage to Care

Linkage to care is measured by the documentation of CD4, viral load or genotype tests performed within one month of diagnosis.

#### Viral Suppression

Viral suppression is measured by a viral load less than 200 copies/mL performed within six months of diagnosis.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2021 and Reported as of 02/28/2022

Table 1. Diagnoses of HIV infection by age and year of initial HIV diagnosis (1), San Francisco, 2010-2021

Age at initial HIV diagnosis (years)	Year of initial HIV diagnosis					
	2010 No. (%)	2011 No. (%)	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)
0 - 12	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
13 - 17	3 ( 0.6)	0 ( 0.0)	0 ( 0.0)	1 ( 0.2)	1 ( 0.3)	3 ( 1.0)
18 - 24	61 (12.7)	46 (10.7)	63 (13.3)	63 (15.6)	41 (12.7)	38 (12.8)
25 - 29	70 (14.6)	68 (15.9)	78 (16.5)	81 (20.1)	59 (18.3)	74 (24.8)
30 - 39	148 (30.8)	118 (27.5)	143 (30.2)	112 (27.8)	94 (29.2)	89 (29.9)
40 - 49	130 (27.1)	130 (30.3)	133 (28.1)	99 (24.6)	74 (23.0)	63 (21.1)
50 - 59	52 (10.8)	52 (12.1)	45 ( 9.5)	34 ( 8.4)	40 (12.4)	18 ( 6.0)
60 +	16 ( 3.3)	15 ( 3.5)	12 ( 2.5)	13 ( 3.2)	13 ( 4.0)	13 ( 4.4)
<b>Total</b>	<b>480 ( 100)</b>	<b>429 ( 100)</b>	<b>474 ( 100)</b>	<b>403 ( 100)</b>	<b>322 ( 100)</b>	<b>298 ( 100)</b>

Age at initial HIV diagnosis (years)	Year of initial HIV diagnosis					
	2016 No. (%)	2017 No. (%)	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)
0 - 12	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
13 - 17	1 ( 0.4)	3 ( 1.3)	1 ( 0.5)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
18 - 24	34 (14.2)	26 (10.9)	32 (15.2)	17 ( 9.9)	17 (12.4)	12 ( 7.5)
25 - 29	53 (22.1)	41 (17.2)	43 (20.4)	23 (13.4)	22 (16.1)	30 (18.8)
30 - 39	79 (32.9)	83 (34.7)	65 (30.8)	66 (38.4)	45 (32.8)	55 (34.4)
40 - 49	36 (15.0)	49 (20.5)	43 (20.4)	30 (17.4)	26 (19.0)	33 (20.6)
50 - 59	25 (10.4)	26 (10.9)	17 ( 8.1)	21 (12.2)	22 (16.1)	23 (14.4)
60 +	12 ( 5.0)	11 ( 4.6)	10 ( 4.7)	15 ( 8.7)	5 ( 3.6)	7 ( 4.4)
<b>Total</b>	<b>240 ( 100)</b>	<b>239 ( 100)</b>	<b>211 ( 100)</b>	<b>172 ( 100)</b>	<b>137 ( 100)</b>	<b>160 ( 100)</b>

(1) Includes persons diagnosed with HIV infection regardless of disease stage. The initial year of HIV diagnosis was determined based on the earliest date of positive HIV antibody test, positive HIV antigen/antibody combination test, detectable viral load, physician-documented diagnosis in absence of sufficient laboratory evidence, or patient self-report of a positive HIV test. Data in recent years are incomplete due to delays in case reporting.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2021 and Reported as of 02/28/2022

Table 2. Diagnoses of HIV infection stage 3 (AIDS) by age and year of AIDS diagnosis (1), San Francisco, 2010-2021

Age at AIDS diagnosis (years)	Year of AIDS diagnosis					
	2010 No. (%)	2011 No. (%)	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)
0 - 12	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
13 - 17	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
18 - 24	15 ( 5.0)	12 ( 4.8)	11 ( 4.5)	10 ( 5.3)	6 ( 4.3)	4 ( 3.2)
25 - 29	27 ( 9.0)	21 ( 8.3)	26 (10.7)	17 ( 9.0)	13 ( 9.4)	9 ( 7.1)
30 - 39	74 (24.6)	62 (24.6)	60 (24.6)	43 (22.8)	41 (29.5)	35 (27.8)
40 - 49	100 (33.2)	99 (39.3)	83 (34.0)	60 (31.7)	40 (28.8)	36 (28.6)
50 - 59	62 (20.6)	49 (19.4)	44 (18.0)	38 (20.1)	26 (18.7)	28 (22.2)
60 +	23 ( 7.6)	9 ( 3.6)	20 ( 8.2)	21 (11.1)	13 ( 9.4)	14 (11.1)
<b>Total</b>	<b>301 ( 100)</b>	<b>252 ( 100)</b>	<b>244 ( 100)</b>	<b>189 ( 100)</b>	<b>139 ( 100)</b>	<b>126 ( 100)</b>

Age at AIDS diagnosis (years)	Year of AIDS diagnosis					
	2016 No. (%)	2017 No. (%)	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)
0 - 12	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
13 - 17	0 ( 0.0)	1 ( 0.8)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
18 - 24	2 ( 2.1)	1 ( 0.8)	3 ( 2.6)	2 ( 1.8)	2 ( 2.3)	1 ( 1.1)
25 - 29	8 ( 8.2)	15 (11.5)	12 (10.4)	9 ( 8.1)	8 ( 9.3)	11 (12.6)
30 - 39	27 (27.8)	32 (24.4)	32 (27.8)	33 (29.7)	26 (30.2)	18 (20.7)
40 - 49	23 (23.7)	41 (31.3)	21 (18.3)	25 (22.5)	17 (19.8)	22 (25.3)
50 - 59	19 (19.6)	15 (11.5)	26 (22.6)	24 (21.6)	18 (20.9)	23 (26.4)
60 +	18 (18.6)	26 (19.8)	21 (18.3)	18 (16.2)	15 (17.4)	12 (13.8)
<b>Total</b>	<b>97 ( 100)</b>	<b>131 ( 100)</b>	<b>115 ( 100)</b>	<b>111 ( 100)</b>	<b>86 ( 100)</b>	<b>87 ( 100)</b>

(1) Data in recent years are incomplete due to delays in case reporting.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2021 and Reported as of 02/28/2022

**Table 3. Diagnoses of HIV infection by gender and year of initial HIV diagnosis (1), San Francisco, 2010-2021**

Gender (2)	Year of initial HIV diagnosis					
	2010 No. (%)	2011 No. (%)	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)
Men	427 (89.0)	375 (87.4)	435 (91.8)	370 (91.8)	297 (92.2)	261 (87.6)
Women	36 (7.5)	41 (9.6)	27 (5.7)	21 (5.2)	13 (4.0)	29 (9.7)
Trans Women	17 (3.5)	13 (3.0)	12 (2.5)	12 (3.0)	12 (3.7)	8 (2.7)
<b>Total</b>	<b>480 (100)</b>	<b>429 (100)</b>	<b>474 (100)</b>	<b>403 (100)</b>	<b>322 (100)</b>	<b>298 (100)</b>

Gender (2)	Year of initial HIV diagnosis					
	2016 No. (%)	2017 No. (%)	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)
Men	205 (85.4)	206 (86.2)	185 (87.7)	143 (83.1)	111 (81.0)	124 (77.5)
Women	25 (10.4)	27 (11.3)	17 (8.1)	14 (8.1)	18 (13.1)	23 (14.4)
Trans Women	9 (3.8)	6 (2.5)	8 (3.8)	13 (7.6)	7 (5.1)	12 (7.5)
<b>Total</b>	<b>240 (100)</b>	<b>239 (100)</b>	<b>211 (100)</b>	<b>172 (100)</b>	<b>137 (100)</b>	<b>160 (100)</b>

(1) Includes persons diagnosed with HIV infection regardless of disease stage. The initial year of HIV diagnosis was determined based on the earliest date of positive HIV antibody test, positive HIV antigen/antibody combination test, detectable viral load, physician-documented diagnosis in absence of sufficient laboratory evidence, or patient self-report of a positive HIV test. Data in recent years are incomplete due to delays in case reporting.

(2) Data on trans men are not released separately due to small numbers.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2021 and Reported as of 02/28/2022

Table 4. Diagnoses of HIV infection stage 3 (AIDS) by gender and year of AIDS diagnosis (1), San Francisco, 2010-2021

Gender (2)	Year of AIDS diagnosis					
	2010 No. (%)	2011 No. (%)	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)
Men	268 (89.0)	214 (84.9)	211 (86.5)	166 (87.8)	125 (89.9)	99 (78.6)
Women	17 (5.6)	24 (9.5)	24 (9.8)	17 (9.0)	7 (5.0)	19 (15.1)
Trans Women	16 (5.3)	14 (5.6)	9 (3.7)	6 (3.2)	7 (5.0)	8 (6.3)
<b>Total</b>	<b>301 (100)</b>	<b>252 (100)</b>	<b>244 (100)</b>	<b>189 (100)</b>	<b>139 (100)</b>	<b>126 (100)</b>

Gender (2)	Year of AIDS diagnosis					
	2016 No. (%)	2017 No. (%)	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)
Men	82 (84.5)	103 (78.6)	100 (87.0)	97 (87.4)	70 (81.4)	70 (80.5)
Women	11 (11.3)	22 (16.8)	12 (10.4)	7 (6.3)	11 (12.8)	10 (11.5)
Trans Women	3 (3.1)	6 (4.6)	3 (2.6)	7 (6.3)	5 (5.8)	6 (6.9)
<b>Total</b>	<b>97 (100)</b>	<b>131 (100)</b>	<b>115 (100)</b>	<b>111 (100)</b>	<b>86 (100)</b>	<b>87 (100)</b>

(1) Data in recent years are incomplete due to delays in case reporting.

(2) Data on trans men are not released separately due to small numbers.



## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2021 and Reported as of 02/28/2022

Table 5. Diagnoses of HIV infection by race/ethnicity and year of initial HIV diagnosis (1), San Francisco, 2010-2021

Race/ethnicity	Year of initial HIV diagnosis					
	2010 No. (%)	2011 No. (%)	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)
White	226 (47.1)	223 (52.0)	227 (47.9)	180 (44.7)	134 (41.6)	120 (40.3)
Black/African American	67 (14.0)	63 (14.7)	53 (11.2)	47 (11.7)	33 (10.2)	44 (14.8)
Latinx	112 (23.3)	85 (19.8)	117 (24.7)	111 (27.5)	94 (29.2)	78 (26.2)
Asian/Pacific Islander/ Native American	44 ( 9.2)	38 ( 8.9)	55 (11.6)	50 (12.4)	46 (14.3)	37 (12.4)
Multiple races	30 ( 6.3)	19 ( 4.4)	21 ( 4.4)	14 ( 3.5)	15 ( 4.7)	18 ( 6.0)
<b>Total (2)</b>	<b>480 ( 100)</b>	<b>429 ( 100)</b>	<b>474 ( 100)</b>	<b>403 ( 100)</b>	<b>322 ( 100)</b>	<b>298 ( 100)</b>

Race/ethnicity	Year of initial HIV diagnosis					
	2016 No. (%)	2017 No. (%)	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)
White	91 (37.9)	82 (34.3)	60 (28.4)	59 (34.3)	40 (29.2)	52 (32.5)
Black/African American	33 (13.8)	39 (16.3)	41 (19.4)	29 (16.9)	27 (19.7)	26 (16.3)
Latinx	71 (29.6)	72 (30.1)	83 (39.3)	56 (32.6)	52 (38.0)	61 (38.1)
Asian/Pacific Islander/ Native American	38 (15.8)	33 (13.8)	21 (10.0)	23 (13.4)	17 (12.4)	18 (11.3)
Multiple races	7 ( 2.9)	13 ( 5.4)	6 ( 2.8)	5 ( 2.9)	1 ( 0.7)	3 ( 1.9)
<b>Total (2)</b>	<b>240 ( 100)</b>	<b>239 ( 100)</b>	<b>211 ( 100)</b>	<b>172 ( 100)</b>	<b>137 ( 100)</b>	<b>160 ( 100)</b>

(1) Includes persons diagnosed with HIV infection regardless of disease stage. The initial year of HIV diagnosis was determined based on the earliest date of positive HIV antibody test, positive HIV antigen/antibody combination test, detectable viral load, physician-documented diagnosis in absence of sufficient laboratory evidence, or patient self-report of a positive HIV test. Data in recent years are incomplete due to delays in case reporting.

(2) Total includes persons with unknown race.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2021 and Reported as of 02/28/2022

Table 6. Diagnoses of HIV infection stage 3 (AIDS) by race/ethnicity and year of AIDS diagnosis (1), San Francisco, 2010-2021

Race/ethnicity	Year of AIDS diagnosis					
	2010 No. (%)	2011 No. (%)	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)
White	143 (47.5)	128 (50.8)	120 (49.2)	92 (48.7)	52 (37.4)	61 (48.4)
Black/African American	50 (16.6)	45 (17.9)	40 (16.4)	30 (15.9)	28 (20.1)	19 (15.1)
Latinx	65 (21.6)	48 (19.0)	55 (22.5)	37 (19.6)	32 (23.0)	32 (25.4)
Asian/Pacific Islander/ Native American	24 ( 8.0)	14 ( 5.6)	14 ( 5.7)	18 ( 9.5)	17 (12.2)	5 ( 4.0)
Multiple races	19 ( 6.3)	17 ( 6.7)	15 ( 6.1)	12 ( 6.3)	10 ( 7.2)	9 ( 7.1)
<b>Total (2)</b>	<b>301 ( 100)</b>	<b>252 ( 100)</b>	<b>244 ( 100)</b>	<b>189 ( 100)</b>	<b>139 ( 100)</b>	<b>126 ( 100)</b>

Race/ethnicity	Year of AIDS diagnosis					
	2016 No. (%)	2017 No. (%)	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)
White	42 (43.3)	52 (39.7)	36 (31.3)	43 (38.7)	38 (44.2)	29 (33.3)
Black/African American	15 (15.5)	26 (19.8)	18 (15.7)	23 (20.7)	17 (19.8)	15 (17.2)
Latinx	21 (21.6)	35 (26.7)	41 (35.7)	21 (18.9)	21 (24.4)	29 (33.3)
Asian/Pacific Islander/ Native American	12 (12.4)	13 ( 9.9)	10 ( 8.7)	14 (12.6)	8 ( 9.3)	10 (11.5)
Multiple races	7 ( 7.2)	5 ( 3.8)	10 ( 8.7)	10 ( 9.0)	2 ( 2.3)	4 ( 4.6)
<b>Total (2)</b>	<b>97 ( 100)</b>	<b>131 ( 100)</b>	<b>115 ( 100)</b>	<b>111 ( 100)</b>	<b>86 ( 100)</b>	<b>87 ( 100)</b>

(1) Data in recent years are incomplete due to delays in case reporting.

(2) Total includes persons with unknown race.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2021 and Reported as of 02/28/2022

Table 7. Diagnoses of HIV infection by transmission category and year of initial HIV diagnosis (1), San Francisco, 2010-2021

Transmission category (2)	Year of initial HIV diagnosis					
	2010 No. (%)	2011 No. (%)	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)
Men who have sex with men (MSM)	315 (65.6)	303 (70.6)	364 (76.8)	310 (76.9)	244 (75.8)	225 (75.5)
People who inject drugs (PWID)	40 ( 8.3)	29 ( 6.8)	21 ( 4.4)	21 ( 5.2)	24 ( 7.5)	17 ( 5.7)
MSM-PWID	69 (14.4)	61 (14.2)	52 (11.0)	51 (12.7)	42 (13.0)	28 ( 9.4)
Heterosexual (3)	38 ( 7.9)	29 ( 6.8)	28 ( 5.9)	16 ( 4.0)	10 ( 3.1)	22 ( 7.4)
Transfusion/Hemophilia	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Perinatal	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Other/Unknown	18 ( 3.8)	7 ( 1.6)	9 ( 1.9)	5 ( 1.2)	2 ( 0.6)	6 ( 2.0)
<b>Total</b>	<b>480 ( 100)</b>	<b>429 ( 100)</b>	<b>474 ( 100)</b>	<b>403 ( 100)</b>	<b>322 ( 100)</b>	<b>298 ( 100)</b>

Transmission category (2)	Year of initial HIV diagnosis					
	2016 No. (%)	2017 No. (%)	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)
Men who have sex with men (MSM)	168 (70.0)	147 (61.5)	136 (64.5)	116 (67.4)	89 (65.0)	87 (54.4)
People who inject drugs (PWID)	21 ( 8.8)	26 (10.9)	27 (12.8)	12 ( 7.0)	14 (10.2)	18 (11.3)
MSM-PWID	27 (11.3)	33 (13.8)	28 (13.3)	20 (11.6)	14 (10.2)	24 (15.0)
Heterosexual (3)	17 ( 7.1)	16 ( 6.7)	12 ( 5.7)	9 ( 5.2)	8 ( 5.8)	9 ( 5.6)
Transfusion/Hemophilia	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Perinatal	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Other/Unknown	7 ( 2.9)	17 ( 7.1)	8 ( 3.8)	15 ( 8.7)	12 ( 8.8)	22 (13.8)
<b>Total</b>	<b>240 ( 100)</b>	<b>239 ( 100)</b>	<b>211 ( 100)</b>	<b>172 ( 100)</b>	<b>137 ( 100)</b>	<b>160 ( 100)</b>

- (1) Includes persons diagnosed with HIV infection regardless of disease stage. The initial year of HIV diagnosis was determined based on the earliest date of positive HIV antibody test, positive HIV antigen/antibody combination test, detectable viral load, physician-documented diagnosis in absence of sufficient laboratory evidence, or patient self-report of a positive HIV test. Data in recent years are incomplete due to delays in case reporting.
- (2) Persons with more than one risk factor (other than the combinations listed in the tables) are tabulated only in the most likely transmission category.
- (3) Includes persons who have had heterosexual contact with a person with HIV or with a person who is at risk for HIV.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2021 and Reported as of 02/28/2022

**Table 8. Diagnoses of HIV infection stage 3 (AIDS) by transmission category and year of AIDS diagnosis (1), San Francisco, 2010-2021**

Transmission category (2)	Year of AIDS diagnosis					
	2010 No. (%)	2011 No. (%)	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)
Men who have sex with men (MSM)	170 (56.5)	148 (58.7)	152 (62.3)	112 (59.3)	95 (68.3)	72 (57.1)
People who inject drugs (PWID)	23 ( 7.6)	33 (13.1)	23 ( 9.4)	19 (10.1)	16 (11.5)	19 (15.1)
MSM-PWID	84 (27.9)	50 (19.8)	43 (17.6)	45 (23.8)	21 (15.1)	24 (19.0)
Heterosexual (3)	19 ( 6.3)	17 ( 6.7)	21 ( 8.6)	12 ( 6.3)	7 ( 5.0)	10 ( 7.9)
Transfusion/Hemophilia	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Perinatal	0 ( 0.0)	1 ( 0.4)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Other/Unknown	5 ( 1.7)	3 ( 1.2)	5 ( 2.0)	1 ( 0.5)	0 ( 0.0)	1 ( 0.8)
<b>Total</b>	<b>301 ( 100)</b>	<b>252 ( 100)</b>	<b>244 ( 100)</b>	<b>189 ( 100)</b>	<b>139 ( 100)</b>	<b>126 ( 100)</b>

Transmission category (2)	Year of AIDS diagnosis					
	2016 No. (%)	2017 No. (%)	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)
Men who have sex with men (MSM)	58 (59.8)	63 (48.1)	67 (58.3)	62 (55.9)	44 (51.2)	34 (39.1)
People who inject drugs (PWID)	12 (12.4)	14 (10.7)	14 (12.2)	13 (11.7)	7 ( 8.1)	20 (23.0)
MSM-PWID	16 (16.5)	29 (22.1)	22 (19.1)	27 (24.3)	26 (30.2)	19 (21.8)
Heterosexual (3)	11 (11.3)	19 (14.5)	8 ( 7.0)	6 ( 5.4)	4 ( 4.7)	7 ( 8.0)
Transfusion/Hemophilia	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Perinatal	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	1 ( 1.1)
Other/Unknown	0 ( 0.0)	6 ( 4.6)	4 ( 3.5)	3 ( 2.7)	5 ( 5.8)	6 ( 6.9)
<b>Total</b>	<b>97 ( 100)</b>	<b>131 ( 100)</b>	<b>115 ( 100)</b>	<b>111 ( 100)</b>	<b>86 ( 100)</b>	<b>87 ( 100)</b>

(1) Data in recent years are incomplete due to delays in case reporting.

(2) Persons with more than one risk factor (other than the combinations listed in the tables) are tabulated only in the most likely transmission category.

(3) Includes persons who have had heterosexual contact with a person with HIV or with a person who is at risk for HIV.

**HIV Semi-Annual Surveillance Report  
Cases Diagnosed as of 12/31/2021 and  
Reported as of 02/28/2022**

Table 9. Diagnoses of HIV infection, HIV deaths and persons living with HIV as of 12/31/2021 by year, San Francisco, 2002-2021

Year	Number of cases diagnosed per year (1)	Number of deaths occurred per year (1)	Number of persons living with HIV infection (1)
2002 (2)	650	347	13304
2003	637	330	13611
2004	689	335	13965
2005	555	343	14177
2006	542	325	14394
2007	534	323	14605
2008	526	264	14867
2009	476	250	15093
2010	480	244	15329
2011	429	236	15522
2012	474	235	15761
2013	403	258	15906
2014	322	239	15989
2015	298	256	16031
2016	240	234	16037
2017	239	253	16023
2018	211	257	15977
2019	172	263	15886
2020	137	286	15737
2021	160	270	15627

(1) Data in recent years are incomplete due to delays in case/death reporting.

(2) Year of the mandatory reporting of HIV non-AIDS cases in California began.

**HIV Semi-Annual Surveillance Report  
Cases Diagnosed as of 12/31/2021 and  
Reported as of 02/28/2022**

Table 10. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS as of 12/31/2021 by year, San Francisco, 1980-2021

Year	Number of cases diagnosed per year (1)	Number of deaths occurred per year (1)	Number of persons living with AIDS (1)
1980	3	0	3
1981	26	8	21
1982	99	32	88
1983	274	111	251
1984	557	273	535
1985	859	534	860
1986	1236	807	1289
1987	1636	878	2047
1988	1762	1038	2771
1989	2159	1278	3652
1990	2043	1364	4331
1991	2284	1512	5103
1992	2324	1640	5787
1993	2061	1603	6245
1994	1774	1600	6419
1995	1548	1485	6482
1996	1065	992	6555
1997	793	424	6924
1998	682	401	7205
1999	574	353	7426
2000	552	349	7629
2001	505	324	7810
2002	478	320	7968
2003	543	294	8217
2004	476	300	8393
2005	475	308	8560
2006	451	287	8724
2007	443	269	8898
2008	434	227	9105
2009	325	208	9222
2010	301	193	9330
2011	252	190	9392
2012	244	181	9455
2013	189	191	9453
2014	139	188	9404
2015	126	203	9327
2016	97	184	9240
2017	131	202	9169
2018	115	208	9076
2019	111	192	8995
2020	86	207	8874
2021	87	198	8763
Total	30319	21556	

(1) Data in recent years are incomplete due to delays in case/death reporting.

**HIV Semi-Annual Surveillance Report  
Cases Diagnosed as of 12/31/2021 and  
Reported as of 02/28/2022**

**Table 11. Persons living with HIV infection as of 12/31/2021 by age, gender and race/ethnicity, San Francisco**

Current age (years)	White No. (%)	Black/African American No. (%)	Latinx No. (%)	Asian/ Pacific Islander/ Native American No. (%)	Multiple races No. (%)	Total (1) No. (%)
<b>Men</b>						
0 - 12	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
13 - 17	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
18 - 24	4 ( 0.0)	11 ( 0.8)	15 ( 0.5)	8 ( 0.8)	1 ( 0.2)	39 ( 0.3)
25 - 29	45 ( 0.5)	42 ( 3.1)	82 ( 2.8)	26 ( 2.7)	10 ( 2.1)	205 ( 1.4)
30 - 39	484 ( 5.7)	153 (11.2)	484 (16.6)	170 (17.7)	47 ( 9.7)	1338 ( 9.4)
40 - 49	1038 (12.1)	181 (13.2)	643 (22.0)	250 (26.0)	110 (22.6)	2223 (15.5)
50 - 59	2969 (34.7)	406 (29.7)	973 (33.3)	315 (32.7)	171 (35.1)	4836 (33.8)
60 +	4017 (46.9)	574 (42.0)	722 (24.7)	193 (20.1)	148 (30.4)	5657 (39.6)
<b>Men Total</b>	<b>8557 ( 100)</b>	<b>1367 ( 100)</b>	<b>2919 ( 100)</b>	<b>962 ( 100)</b>	<b>487 ( 100)</b>	<b>14298 ( 100)</b>
<b>Women</b>						
0 - 12	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
13 - 17	0 ( 0.0)	1 ( 0.3)	1 ( 0.5)	0 ( 0.0)	0 ( 0.0)	2 ( 0.2)
18 - 24	0 ( 0.0)	3 ( 0.9)	2 ( 0.9)	0 ( 0.0)	2 ( 4.9)	7 ( 0.8)
25 - 29	3 ( 1.3)	8 ( 2.5)	13 ( 6.0)	3 ( 3.9)	3 ( 7.3)	30 ( 3.3)
30 - 39	25 (10.5)	30 ( 9.3)	38 (17.4)	6 ( 7.8)	3 ( 7.3)	102 (11.4)
40 - 49	41 (17.2)	46 (14.3)	42 (19.3)	19 (24.7)	12 (29.3)	161 (17.9)
50 - 59	85 (35.7)	100 (31.1)	62 (28.4)	27 (35.1)	12 (29.3)	286 (31.8)
60 +	84 (35.3)	134 (41.6)	60 (27.5)	22 (28.6)	9 (22.0)	310 (34.5)
<b>Women Total</b>	<b>238 ( 100)</b>	<b>322 ( 100)</b>	<b>218 ( 100)</b>	<b>77 ( 100)</b>	<b>41 ( 100)</b>	<b>898 ( 100)</b>
<b>Trans Women</b>	<b>74 ( 100)</b>	<b>127 ( 100)</b>	<b>152 ( 100)</b>	<b>43 ( 100)</b>	<b>25 ( 100)</b>	<b>421 ( 100)</b>

(1) Total includes persons with unknown race. Data on trans men are not released separately due to small numbers.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2021 and Reported as of 02/28/2022

Table 12. Persons living with HIV infection as of 12/31/2021 by transmission category, gender and race/ethnicity, San Francisco

Transmission category (1)	White No. (%)	Black/ African American No. (%)	Latinx No. (%)	Asian/Pacific Islander/ Native American No. (%)	Multiple races No. (%)	Total (2) No. (%)
<b>Men</b>						
Men who have sex with men (MSM)	7029 (82.1)	848 (62.0)	2400 (82.2)	821 (85.3)	348 (71.5)	11447 (80.1)
People who inject drugs (PWID)	156 ( 1.8)	167 (12.2)	67 ( 2.3)	22 ( 2.3)	19 ( 3.9)	431 ( 3.0)
MSM-IDU	1290 (15.1)	249 (18.2)	345 (11.8)	82 ( 8.5)	108 (22.2)	2074 (14.5)
Heterosexual (3)	31 ( 0.4)	62 ( 4.5)	55 ( 1.9)	19 ( 2.0)	7 ( 2.0)	174 ( 1.2)
Transfusion/Hemophiliac	5 ( 0.1)	1 ( 0.1)	2 ( 0.1)	3 ( 0.3)	0 ( 0.0)	11 ( 0.1)
Perinatal	1 ( 0.0)	3 ( 0.2)	3 ( 0.1)	1 ( 0.1)	2 ( 0.4)	10 ( 0.1)
Other/Unknown	45 ( 0.5)	37 ( 2.7)	47 ( 1.6)	14 ( 1.5)	3 ( 0.6)	151 ( 1.1)
<b>Men Total</b>	<b>8557 ( 100)</b>	<b>1367 ( 100)</b>	<b>2919 ( 100)</b>	<b>962 ( 100)</b>	<b>487 ( 100)</b>	<b>14298 ( 100)</b>
<b>Women</b>						
People who inject drugs (PWID)	134 (56.3)	152 (47.2)	62 (28.4)	13 (16.9)	22 (53.7)	383 (42.7)
Heterosexual (3)	77 (32.4)	136 (42.2)	116 (53.2)	54 (70.1)	11 (26.8)	394 (43.9)
Transfusion/Hemophilia	5 ( 2.1)	1 ( 0.3)	2 ( 0.9)	2 ( 2.6)	0 ( 0.0)	10 ( 1.1)
Perinatal	1 ( 0.4)	6 ( 1.9)	9 ( 4.1)	0 ( 0.0)	2 ( 4.9)	18 ( 2.0)
Other/Unknown	21 ( 8.8)	27 ( 8.4)	29 (13.3)	8 (10.4)	6 (14.6)	93 (10.4)
<b>Women Total</b>	<b>238 ( 100)</b>	<b>322 ( 100)</b>	<b>218 ( 100)</b>	<b>77 ( 100)</b>	<b>41 ( 100)</b>	<b>898 ( 100)</b>
<b>Trans Women</b>	<b>74 ( 100)</b>	<b>127 ( 100)</b>	<b>152 ( 100)</b>	<b>43 ( 100)</b>	<b>25 ( 100)</b>	<b>421 ( 100)</b>

(1) Persons with more than one risk factor (other than the combinations listed in the tables) are tabulated only in the most likely transmission category.

(2) Total includes persons with unknown race. Data on trans men are not released separately due to small numbers.

(3) Includes persons who have had heterosexual contact with a person with HIV or with a person who is at risk for HIV.